Retatrutide has emerged as a new pharmaceutical in the fight against obesity. This groundbreaking drug, belonging to a dual GLP-1 and GIP receptor agonist, demonstrates promising results in clinical trials. By boosting these receptors, Retatrutide reduces hunger pangs, {promotesglucose regulation, and ultimately leads to significant reduction in bo